Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Firle, South Australia-based Avance Clinical operates in Biotechnology Research. It is privately held, and its site is avancecro.com. It holds three addresses on record across three office countries. Headcount on record is 392. Its work is tagged oncology and infectious diseases. One Australian registration (ABN) is a confirmed match. Its latest round on record is Private equity, with no amount recorded. It is listed alongside four similar brands, mostly in Biotechnology Research.
ABN47630528719
| AVANCE CLINICAL PTY LTD | ABN 47630528719 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in early phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success.
Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies. With a focus on agility, innovation, and cost-effectiveness, we deliver fast results backed by robust, globally accepted data.
With expertise spanning over 250+ indications, across all therapeutic areas, over the last three decades, Avance Clinical consistently delivers data recognized by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA.
What sets us apart is our personalized service tailored to each client, ensuring customized, flexible solutions rather than a one-size-fits-all approach.
www.avancecro.com
| Countries | 3 |
|---|---|
| Primary country | AU |
All codes: AU IN US
| Rounds | 1 |
|---|---|
| Axis | 2019 to 2026 |
| Private equity · 18 Feb 2022 | not disclosed |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
One South Australia entity on the ABR: AVANCE CLINICAL PTY LTD (ABN 47 630 528 719), high confidence.
392 counted staff profiles at January 2026, inside the self-reported 201–500 band.
Three addresses on record across 3 countries. Primary: 213 Glynburn Rd, Firle, SOUTH AUSTRALIA 5070.
One round. Latest 18 February 2022: private equity, investor Riverside Company, no amount recorded.
12 tags on the brand's own list, among them oncology and infectious diseases.
95 profiles list Avance Clinical as a peer — 99th percentile in Biotechnology Research. It lists ten peers of its own. Southern Star Research and Emerald Clinical list it back.